2008
DOI: 10.1016/j.bone.2007.08.038
|View full text |Cite
|
Sign up to set email alerts
|

Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: A case–control study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

7
144
0
2

Year Published

2012
2012
2024
2024

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 183 publications
(153 citation statements)
references
References 25 publications
7
144
0
2
Order By: Relevance
“…We used to do experiments to verify the apoptosis inducing mechanism of ZOL on GCT. Moreover, significant calcification around the lesion was observed after ZOL adjuvant therapy of GCT (Tse et al, 2008). We think ZOL may also induces osteogenic differentiation on GCTSC.…”
Section: Stimulation Of Osteogenic Differentiation In Stromal Cells Omentioning
confidence: 76%
See 2 more Smart Citations
“…We used to do experiments to verify the apoptosis inducing mechanism of ZOL on GCT. Moreover, significant calcification around the lesion was observed after ZOL adjuvant therapy of GCT (Tse et al, 2008). We think ZOL may also induces osteogenic differentiation on GCTSC.…”
Section: Stimulation Of Osteogenic Differentiation In Stromal Cells Omentioning
confidence: 76%
“…Recently, the anti-osteolytic and anti-tumor function of bisphosphonates by inhibition of farnesylation and geranylgeranylation of RAS related proteins has attracted much attention. The potential of bisphosphonates in killing tumor cells and relieve the clinical symptoms of GCT has been observed Tse et al, 2008). However, there was little evidence to reveal the therapeutic mechanism of bisphosphonate as an adjuvant in GCT.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Thomas et al [41] reported their results of denosumab treatment in 35 patients with bone GCTs and found 30 of 35 patients had a tumor response assessed by histology or radiology. As was reported [4,41,42], bisphosphonate and denosumab could be used for treatment of recurrent or metastatic disease or for primary inoperable pelvic and sacral tumors.…”
Section: Discussionmentioning
confidence: 84%
“…There have been some recent reports of bisphosphonate [4,42] and denosumab [41] for treatment of GCTs of bone. The rationale for bisphosphonate treatment is that these compounds reduce osteoclast numbers and inhibit osteoclastic destruction [4].…”
Section: Discussionmentioning
confidence: 99%